Citations

Clear

3138 citation(s) found for "Smith, AM".

Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, Na , Qiao, Wenhui , Li, Fuyao , Ren, Yingxue , Zheng, Jiaying , Martens, Yuka A. , Wang, Xusheng , Li, Ling , Liu, Chia‐Chen , Chen, Kai , Zhu, Yiyang , Ikezu, Tadafumi C. , Li, Zonghua , Meneses, Axel , Jin, Yunjung , Chen, Yixing , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L. , Xie, Manling , Liu, Yong , Umpierre, Anthony D. , Haruwaka, Koichiro , Quicksall, Zachary , Störz, Peter , Asmann, Yan W. , Wu, Long‐Jun , Bu, Guojun , Meneses, Axel D , Knight, Joshua A , Chen, Yixing , Bastea, Ligia , Linares, Cynthia , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L , Xie, Manling , Liu, Yong U , Umpierre, Anthony D , Haruwaka, Koichiro , Quicksall, Zachary S , Storz, Peter , Asmann, Yan W , Wu, Long-Jun , Bu, Guojun , Liu, Chia-Chen , Zhao, Na , Li, Fuyao , Zheng, Jiaying , Knight, Joshua A. , Bastea, Ligia I.

Mayo Clinic

Journal of Experimental Medicine | September 15, 2022 | Volume: 219 | Issue: 12 | Pages: No page available

10.1084/jem.20212479 | PMID 36107206 Get It

TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections
Blaskovich, Mark A. T. , Hansford, Karl A. , Butler, Mark S. , Ramu, Soumya , Kavanagh, Angela M. , Prasetyoputri, Anggia , Pitt, Miranda E. , Huang, Johnny X. , Lindahl, Fredrik, Ziora, Zyta M. , Bradford, Tanya A. , Muldoon, Craig, Premraj, Rajaratnam , Pelingon, Ruby , Edwards, David J. , Amado, Maite , Woischnig, Anne-Kathrin , Breidenstein, Elena B. M. , Stincone, Anna, Karau, Melissa J. , Greenwood‐Quaintance, Kerryl E. , Wootton, Mandy , James, Meagan L. , Hutton, M. , Mahdi, Layla K. , Trott, Darren J. , Wu, Xiaoqian, Niles, Samantha , Lewis, Kim , Yim, Juwon , Rice, Seth, Rybak, Michael J. , Ishmael, Chad R. , Hori, Kellyn R. , Francis, Kevin P. , Jarrad, Angie M , Prasetyoputri, Anggia , Pitt, Miranda E , Huang, Johnny X , Ziora, Zyta M , Bradford, Tanya , Rajaratnam, Premraj , Pelingon, Ruby , Zhang, Bing , Elliott, Alysha G , Zuegg, Johannes , Coin, Lachlan , Khanna, Nina , Stincone, Anna , Mason, Clive , Cho, Hye-Kyung , Karau, Melissa , Greenwood-Quaintance, Kerryl , Patel, Robin , Wootton, Mandy , James, Meagan L , Hutton, Melanie L , Lyras, Dena , Ogunniyi, Abiodun D , Mahdi, Layla K , Niles, Samantha , Lewis, Kim , Smith, Jordan R , Barber, Katie E , Rybak, Michael J , Ishmael, Chad R , Hori, Kellyn R , Bernthal, Nicholas M , Francis, Kevin P , Paterson, David L. , Cooper, Matthew A , Blaskovich, Mark A T , Edwards, David J., Khan, Nawaz, Patel, Robin , Roberts, Jason A

Mayo Clinic

Science Translational Medicine | September 14, 2022 | Volume: 14 | Issue: 662 | Pages: No page available

10.1126/scitranslmed.abj2381 | PMID 36103517 Get It

Drug-resistant Gram-positive bacterial infections are still a substantial burden on the public health system, with two bacteria ( Staphylococcus aureus and Streptococcus pneumoniae ) accounting for over 1.5 million drug-resistant infections in the United States alone in 2017. In 2019, 250,000 deaths were attributed to these pathogens globally. We have developed a preclinical glycopeptide antibiotic, MCC5145, that has excellent potency (MIC 90 ≤ 0.06 μg/ml) against hundreds of isolates of methicillin-resistant S. aureus (MRSA) and other Gram-positive bacteria, with a greater than 1000-fold margin over mammalian cell cytotoxicity values. The antibiotic has therapeutic in vivo efficacy when dosed subcutaneously in multiple murine models of established bacterial infections, including thigh infection with MRSA and blood septicemia with S. pneumoniae , as well as when dosed orally in an antibiotic-induced Clostridioides difficile infection model. MCC5145 exhibited reduced nephrotoxicity at microbiologically active doses in mice compared to vancomycin. MCC5145 also showed improved activity against biofilms compared to vancomycin, both in vitro and in vivo, and a low propensity to select for drug resistance. Characterization of drug action using a transposon library bioinformatic platform showed a mechanistic distinction from other glycopeptide antibiotics.
Neuro-oncology at the American Society for Clinical Oncology 2022 Annual Meeting
Lukas, Rimas V. , Chmura, Steven J. , Mammoser, Aaron, Smith, Sonali M. , Parney, Ian F. , Li, Jing

Mayo Clinic

Neuro-Oncology Practice | September 10, 2022 | Volume: 9 | Issue: 6 | Pages: 552-558

10.1093/nop/npac071 | PMID 36388417 Get It

Abstract In the following brief report, we highlight the advances in the neuro-oncology space from the ASCO 2022 Annual Meeting. We put into context the phase 2 and 3 trials and how these may alter the standard of care going forward. In addition, we highlight some other earlier work that will lead to future and potentially practice-changing trials.
Substrate Characterization and Outcomes of Catheter Ablation of Ventricular Arrhythmias in Patients With Mitral Annular Disjunction
Ezzeddine, Fatima M. , Siontis, Konstantinos C. , Giudicessi, John R. , Ackerman, Michael J. , Killu, Ammar M. , Deshmukh, Abhishek , Madhavan, Malini , Zyl, Martin van , Vaidya, Vaibhav R. , Karki, Roshan , Munger, Thomas M. , Asirvatham, Samuel J. , Munoz, Freddy Del‐Carpio , Giudicessi, J R , Deshmukh, Abhishek J , van Zyl, Martin , Tseng, A S , McLeod, Christopher J , Asirvatham, Samuel J , Del-Carpio Munoz, Freddy , Ezzeddine, Fatima , Tseng, Andrew S. , McLeod, Christopher J.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | September 8, 2022 | Volume: 15 | Issue: 9 | Pages: No page available

10.1161/circep.122.011088 | PMID 36074649 Get It

Background: Mitral annular disjunction (MAD) has recently been recognized as an arrhythmogenic entity. Data on the electrophysiological substrate as well as the outcomes of catheter ablation of ventricular arrhythmias in patients with MAD is limited. Methods: Forty patients with MAD (mean age 47±15 years; 70% female) underwent catheter ablation for ventricular arrhythmias. Detailed clinical, electrocardiographic, cardiac imaging, and procedural data were collected. Clinical outcomes were compared between patients who had substrate modification in the MAD area and those who did not. Results: Twenty-three (57.5%) patients had ablation for premature ventricular contractions, 10 (25%) patients for sustained ventricular tachycardia, and 7 (17.5%) patients for premature ventricular contraction-triggered ventricular fibrillation. Mean end-systolic MAD length was 10.58±3.49 mm on transthoracic echocardiography. Seventeen (42.5%) patients had preprocedural cardiac magnetic resonance imaging, and 5 (29%) patients had late gadolinium enhancement. Among the 18 (45%) patients who had abnormal local electrograms (low voltage, long-duration, fractionated, isolated mid-diastolic potentials) during electroanatomical mapping, 10 (25%) patients had abnormal electrograms in the anterolateral mitral annulus and/or MAD area. Substrate modification was performed in 10 (25%) patients. Catheter ablation was acutely successful in 36 (90%) patients (elimination of premature ventricular contraction or noninducibility of ventricular tachycardia). After a median follow-up duration of 54.08 (interquartile range, 10.67–89.79) months, premature ventricular contraction burden decreased from a median of 9.75% (interquartile range, 3.25–14) before the ablation to a median of 4% (interquartile range, 1–7.75) after the ablation ( P =0.03 [95% CI, 0.055–6.5]). Eight (20.5%) patients had repeat ablation for ventricular arrhythmias. Substrate modification of the MAD was associated with a trend toward lower rates of repeat ablation (0% versus 26.7%; P =0.16). Conclusions: Patients with MAD have a complex arrhythmogenic substrate, and catheter ablation is effective in reducing recurrence of ventricular arrhythmias. Substrate mapping and ablation may be considered in these patients.
Smoking Status, Nicotine Medication, Vaccination, and COVID-19 Hospital Outcomes: Findings from the COVID EHR Cohort at the University of Wisconsin (CEC-UW) Study
Piasecki, Thomas M. , Smith, Stevens S. , Slutske, Wendy S., Adsit, Robert T. , Conner, Karen L. , Eng, Oliver D., Lazuk, David , Gonzalez, Alec , Jorenby, Douglas E. , D’Angelo, Heather , Kirsch, Julie A. , Williams, Brian , Hayes-Birchler, Todd , Kent, Sean , Kim, Hanna , Lubanski, Stan, Cai, Yuxin , Kashyap, Nitu , Mathew, Jomol , McMahan, Gabriel , Rolland, Betsy , Tindle, Hilary A. , Warren, Graham , An, Lawrence C. , Boyd, Andrew D. , Brunzell, Darlene H., Carrillo, Victor A. , Chen, Li‐Shiun , Davis, James M. , Deshmukh, Vikrant , Dilip, Deepika , Ellerbeck, Edward F. , Jose, Thulasee , Klass, Elizabeth , Tong, Elisa K. , Tsoh, Janice Y. , Wilson, Karen M. , Theobald, Wendy E. , Kent, Sean , Kim, Hanna , Khanna, Niharika , Klass, Elizabeth , Mermelstein, Robin J , Tong, Elisa , Tsoh, Janice Y , Piasecki, Thomas M , Smith, Stevens S , Conner, Karen L , Boyd, Andrew D , Davis, James M , Jose, Thulasee , Baker, Timothy B. , Bolt, Daniel M. , Bernstein, Steven L. , Eng, Oliver D, Nolan, Margaret , Yu, Menggang , Suk, Youmi , Goldstein, Adam O , Iturrate, Eduardo , King, Andrea , Fiore, Michael C.

Mayo Clinic

Nicotine and Tobacco Research | September 7, 2022 | Volume: 25 | Issue: 6 | Pages: 1184-1193

10.1093/ntr/ntac201 | PMID 36069915 Get It

AbstractIntroductionAvailable evidence is mixed concerning associations between smoking status and COVID-19 clinical outcomes. Effects of nicotine replacement therapy (NRT) and vaccination status on COVID-19 outcomes in smokers are unknown.MethodsElectronic health record data from 104 590 COVID-19 patients hospitalized February 1, 2020 to September 30, 2021 in 21 U.S. health systems were analyzed to assess associations of smoking status, in-hospital NRT prescription, and vaccination status with in-hospital death and ICU admission.ResultsCurrent (n = 7764) and never smokers (n = 57 454) did not differ on outcomes after adjustment for age, sex, race, ethnicity, insurance, body mass index, and comorbidities. Former (vs never) smokers (n = 33 101) had higher adjusted odds of death (aOR, 1.11; 95% CI, 1.06–1.17) and ICU admission (aOR, 1.07; 95% CI, 1.04–1.11). Among current smokers, NRT prescription was associated with reduced mortality (aOR, 0.64; 95% CI, 0.50–0.82). Vaccination effects were significantly moderated by smoking status; vaccination was more strongly associated with reduced mortality among current (aOR, 0.29; 95% CI, 0.16–0.66) and former smokers (aOR, 0.47; 95% CI, 0.39–0.57) than for never smokers (aOR, 0.67; 95% CI, 0.57, 0.79). Vaccination was associated with reduced ICU admission more strongly among former (aOR, 0.74; 95% CI, 0.66–0.83) than never smokers (aOR, 0.87; 95% CI, 0.79–0.97).ConclusionsFormer but not current smokers hospitalized with COVID-19 are at higher risk for severe outcomes. SARS-CoV-2 vaccination is associated with better hospital outcomes in COVID-19 patients, especially current and former smokers. NRT during COVID-19 hospitalization may reduce mortality for current smokers.ImplicationsPrior findings regarding associations between smoking and severe COVID-19 disease outcomes have been inconsistent. This large cohort study suggests potential beneficial effects of nicotine replacement therapy on COVID-19 outcomes in current smokers and outsized benefits of SARS-CoV-2 vaccination in current and former smokers. Such findings may influence clinical practice and prevention efforts and motivate additional research that explores mechanisms for these effects.
Developing an Echocardiography-Based, Automatic Deep Learning Framework for the Differentiation of Increased Left Ventricular Wall Thickness Etiologies
Banerjee, Imon , Jeong, Jiwoong , R, Amith Seri, Barry, Timothy , Neuman, Hana, Campany, Megan , Abdou, Merna , O'Shea, Michael P., Smith, Sean B. , Abraham, Bishoy , Hosseini, Seyedeh Maryam , Wang, Yuxiang , Lester, Steven J., Wilansky, Susan , Steidley, Eric, Rosenthal, Julie , Appleton, Christopher, Shen, Win‐Kuang , Grogan, Martha , Kane, G C, Oh, Jae K. , Patel, Bhavik N. , Banerjee, Imon , Li, James , Chao, Chieh‐Ju , O’Shea, Michael, Alsidawi, Said , Oh, Jae K. , Arsanjani, Reza

Mayo Clinic

No container title available | September 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.166257188.84471102/v1 Get It

Aims Increased LV wall thickness is frequently encountered in transthoracic echocardiography (TTE). While accurate and early diagnosis is clinically important, given the differences in available therapeutic options and prognosis, an extensive workup is often required to establish the diagnosis. We propose the first echo-based, automated deep learning model with a fusion architecture to facilitate the evaluation and diagnosis of increased left ventricular (LV) wall thickness. Methods and Results Patients with an established diagnosis of increased LV wall thickness (hypertrophic cardiomyopathy (HCM), cardiac amyloidosis (CA), and hypertensive heart disease (HTN)/others) between 1/2015 to 11/2019 at Mayo Clinic Arizona were identified. The cohort was divided into 80%/10%/10% for training, validation, and testing sets, respectively. Six baseline TTE views were used to optimize a pre-trained InceptionResnetV2 model. Each model output was used to train a meta-learner under a fusion architecture. Model performance was assessed by multiclass area under the receiver operating characteristic curve (AUROC). A total of 586 patients were used for the final analysis (194 HCM, 201 CA, and 191 HTN/others). The mean age was 55.0 years, and 57.8% were male. Among the individual view-dependent models, the apical 4 chamber model had the best performance (AUROC: HCM: 0.94, CA: 0.73, and HTN/other: 0.87). The final fusion model outperformed all the view-dependent models (AUROC: CA: 0.90, HCM: 0.93, and HTN/other: 0.92). Conclusion The echo-based InceptionResnetV2 fusion model can accurately classify the main etiologies of increased LV wall thickness and can facilitate the process of diagnosis and workup.
Methodological Quality Of The Work Of Breathing During Exercise: A Systematic Review
Morris, Sarah J. , Erram, Jyotika, Duke, Joseph W. , Hubbard, Colin D., Smith, Joshua R. , Kelley, Eli F. , Cross, Troy J.

Mayo Clinic

Medicine & Science in Sports & Exercise | September 6, 2022 | Volume: 54 | Issue: 9S | Pages: 279-279

10.1249/01.mss.0000878508.61830.21 Get It

Safety of Scrambler Therapy: A Systematic Review of Complications and Adverse Effects
Wang, Eric J. , Limerick, Gerard, D’Souza, Ryan S. , Lobner, Katie , Williams, Kayode , Cohen, Steven P. , Smith, Thomas J. , Smith, Thomas J , Cohen, Steven P , D'Souza, Ryan S , Wang, Eric

Mayo Clinic

Pain Medicine | September 6, 2022 | Volume: 24 | Issue: 3 | Pages: 325-340

10.1093/pm/pnac137 | PMID 36069623 Get It

AbstractObjectiveThe objective was to qualitatively synthesize all reported cases of complications, adverse effects, side effects, or harms arising from the use of scrambler therapy (ST).Methods and DesignA systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The PubMed, Embase, Scopus, Web of Science, United States National Library of Medicine clinical trials registry, and Cochrane Central Register of Controlled Trials databases were searched from database inception to December 10, 2021. Case reports/series, abstracts, retrospective studies, and prospective studies (e.g., open-label trials, randomized controlled trials) pertaining to ST and any description of a complication, adverse effect, side effect, or harm were screened. The search protocol was developed a priori and registered via the International Prospective Register of Systematic Reviews (PROSPERO ID: CRD42021291838).ResultsA total of six RCTs, 19 prospective open-label trials, and 11 case series / case reports met the inclusion criteria, comprising 1,152 total patients. Two patients experienced contact dermatitis, and one patient reported minor ecchymosis that resolved without intervention. This yielded a composite complication rate of 0.26% (3/1,152). There were zero reported serious adverse events.ConclusionsWhen used in accordance with the treatment protocols described by the United States Food and Drug Administration and device manual, ST is associated with a reported composite complication rate that is orders of magnitude lower than those of invasive neuromodulation devices. ST neuromodulation is a safe alternative for patients who cannot undergo invasive neuromodulation device implantation because of either risk or preference.
Risk Factors for Reduced Function in Women with a History of Breast Cancer
Stoyles, Nicholas, Zucker, David J. , Richards, Blair , Vargo, Mary , Shahpar, Samman , Henderson, Maryanne, Jay, Gina , Smith, Sean R. , Cheville, Andrea , Zucker, David, Gerber, Lynn H.

Mayo Clinic

No container title available | September 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1987491/v1 Get It

Abstract Purpose Breast cancer patients are at risk of losing function during and after treatment. Unfortunately, little is known about the individual and additive effects of specific treatment, disease-related, and demographic factors that may contribute to functional decline. This manuscript reports the results of a multi-center study to evaluate the effects of these factors on function. Methods In this cross-sectional study, women with a history of breast cancer referred to cancer rehabilitation clinics were administered the PROMIS Cancer Function Brief 3D Profile to evaluate function in the domains of physical function, fatigue, and social participation. Clinical and demographic information, including treatment history and disease status, was recorded by clinicians. Patients were analyzed in two groups: those with active disease on antineoplastic treatment, and those with no evidence of disease (NED). A multivariable model was constructed to detect associations between clinical and demographic factors. Results In patients with NED, the presence of chemotherapy-induced peripheral neuropathy (CIPN) was strongly associated with reduced function in all three domains. In those with active disease, having brain metastases was significantly associated with reduced function in all domains and CIPN with reduced physical function. Radiation was associated with improved function in both cohorts. Conclusions Among women seeking rehabilitative care, CIPN and the presence of brain metastases were most strongly associated with a decline in function. The effects of radiation on function were unexpected and may be partially explained by the treatment’s role in symptom management. Clinicians who treat breast cancer should consider a patient’s functional status when providing supportive care.
Critical Care Cardiology Trials Network (CCCTN): a cohort profile
Metkus, Thomas S. , Baird-Zars, Vivian M., Alfonso, Carlos E., Alviar, Carlos L. , Barsness, Gregory W. , Bertić, Mia , Bohula, Erin A. , Burke, James A. , Burstein, Barry , Cooper, Howard A., Daniels, Lori B. , Goldfarb, Michael , Katz, Jason N. , Keeley, Ellen C. , Keller, Norma, Kenigsberg, Benjamin B. , Kontos, Michael C. , Lawler, Patrick R. , Leibner, Evan , Menon, Venu , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Papolos, Alexander , Pierce, Matthew J, Prasad, Rajnish, Pisani, Barbara , Smith, Timothy D., Snell, R. Jeffrey, So, Derek , Ternus, Bradley , Teuteberg, Jeffrey J. , Zakaria, Sammy , Goldfarb, Michael , Pierce, Matthew , Fordyce, Christopher B , Goldfarb, Michael , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Lawler, Patrick , Daniels, Lori B , Bohula, Erin A , Zakaria, Sammy , O'Brien, Connor G , Pierce, Matthew J , Barnett, Christopher F. , Berg, David D. , Burke, James, Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Kwon, Younghoon, Liu, Shuangbo , Prasad, Rajnish, Potter, Brian J , Roswell, Robert O. , Sinha, Shashank S , Shah, Kevin S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 27, 2022 | Volume: 8 | Issue: 7 | Pages: 703-708

10.1093/ehjqcco/qcac055 | PMID 36029517 Get It

AbstractAimsThe aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness.Methods and resultsThe CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness.ConclusionThe CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.